Bajaj Healthcare gets FDA nod to manufacture Hydroxychloroquine Sulphate

18 Apr 2020 Evaluate

Bajaj Healthcare (BHL) has received FDA approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation for its tablets. Hydroxychloroquine Sulphate has been recommended by several countries, including the US, with limited dosage for Covid-19 patients and as a-preventive for high-risk individuals like healthcare workers.

The company will commence its own production of Hydroxychloroquine Sulphate API in the next 3 weeks at its state-of-art manufacturing facilities based at Vadodara, Gujarat and it is estimate to produce 15 Mts of API per month. The company has started the production of Hydroxychloroquine FDF (Tablets ) at Vadodara, Gujarat and is estimated to produce approximately 15 million tablets of Hydroxychloroquine Sulphate.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

559.00 89.90 (19.16%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.